Differences in cell cycle regulation after platinum derivatives treatment in sensitive and cisplatin resistant ovarian cancer cell lines

Horváth, Viktor; Souček, Karel; Šindlerová, Lenka; Hofmanová, Jiřina; Sova, P.; Kozubík, Alois

Number of the records: 1

Differences in cell cycle regulation after platinum derivatives treatment in sensitive and cisplatin resistant ovarian cancer cell lines

1.

SYSNO ASEP	0039222
Document Type	A - Abstract
R&D Document Type	Není vybrán druh dokumentu
Title	Differences in cell cycle regulation after platinum derivatives treatment in sensitive and cisplatin resistant ovarian cancer cell lines
Title	Rozdíly v regulaci buněčného cyklu po ovlivnění ovariálních nádorových buněk platinovými deriváty
Author(s)	Horváth, Viktor (BFU-R) Souček, Karel (BFU-R)_{RID, ORCID} Šindlerová, Lenka (BFU-R)_{RID, ORCID} Hofmanová, Jiřina (BFU-R)_{RID, ORCID} Sova, P. (CZ) Kozubík, Alois (BFU-R)_{RID, ORCID}
Source Title	Chemické listy. - : Česká společnost chemická - ISSN 0009-2770 Roč. 100, č. 5 (2006), s. 383-384
Number of pages	2 s.
Action	Mezioborové setkání mladých biologů, biochemiků a chemiků /6./
Event date	14.06.2006-17.06.2006
VEvent location	Milovy
Country	CZ - Czech Republic
Event type	EUR
Language	eng - English
Country	CZ - Czech Republic
Keywords	ovarian cancer ; cell cycle ; cisplatin
Subject RIV	BO - Biophysics
R&D Projects	1QS500040507 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR)
	PZ-Z2/29 GA MPO - Ministry of Industry and Trade (MPO)
CEZ	AV0Z50040507 - BFU-R (2005-2011)
Annotation	Understanding the specific mechanisms modulating cell cycle effect is necessary for defining the mode of action of LA-12. Therefore, the present study aimed to characterize the effect of LA-12, as compared to cisplatin, on cell cycle modulation and the changes in protein expression levels of cell cycle regulatory proteins (cyclin A, cyclin B1, cdk-2), p53 target genes controlling cell cycle (p21waf1/cip1, Gadd45alpha), apoptosis (Bax), DNA repair (Gadd45alpha), and regulation of p53 stability (Mdm-2) in A2780 (parent, cisplatin sensitive) and A2780cis (cisplatin resistant) ovarian carcinoma cell lines.
Workplace	Institute of Biophysics
Contact	Jana Poláková, polakova@ibp.cz, Tel.: 541 517 244
Year of Publishing	2007

Number of the records: 1